Drugs / anti-EGFR bispecific-armed T cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07343986 Comparator | Mar 2026 → Dec 2027 expected | brain glioblastoma | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-EGFR bispecific-armed T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07343986 ↗ |
| Modality | Cell therapy | “autologous activated T-cells armed with bispecific antibody (EGFR-BATs) that recognize the tumor” NCT07343986 ↗ |
| Target | EGFR | “anti-EGFR bispecific-armed T cells” NCT07343986 ↗ |